% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • scistats scistats Mar 24, 2013 12:22 AM Flag

    Mayo Clinic: Dr. Ayalew Tefferi, M.D. imetelstat for myelofibrosis results before year's end (2013)

    Dr. Ayalew Tefferi, M.D., at the Mayo Clinic has begun an investigator-sponsored pilot study to evaluate safety and efficacy of imetelstat in patients with myelofibrosis, a myeloproliferative neoplasm in the same spectrum of diseases as ET watch?v=XQXcF6CI6yQ

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This could be a $30 stock in no time - imetelstat didn't win the Nobel Prize in 2009 for nothing. We Swedes know where value is (Nobel Prize is from Sweden).

      Sentiment: Strong Buy

    • And Dr. Tefferi's clinic is well-recognized as the national center of excellence for myelofibrosis. So I presume the patients are coming in from pretty much all over.

      Sentiment: Strong Buy

    • So first, regarding the IST trial of myelofibrosis from the Mayo Clinic, can you give us a sense of when we might see initial data out of that? And also, when would you plan on initiating the company-sponsored trial?

      Stephen M. Kelsey - Chief Medical Officer, Head of R & D and Executive Vice President
      I think we had previously said that we expect to have data at Geron in the summer of this year. And clearly, we haven't yet decided because it's an investigator-sponsored trial, we haven't decided how that information will be disseminated into the public domain. ***But I think it's likely to be before the end of this year.*** The timing of the Geron-sponsored trial, I suspect, would be within 6 months of that because we really have to use -- the whole point of that trial is to guide the design of the sponsor trial. So if the data is sufficiently encouraging, then I think there's likely to be a 6- to 9-month lag time between receiving that data and us getting the trial out of the door. I think there's a fairly standard metrics. I'm not sure I'm giving you anything -- any information that's terribly unique to Geron or to this program.

      Sentiment: Strong Buy

    • Purpose
      This pilot clinical trial studies how well imetelstat sodium works in treating patients with primary or secondary myelofibrosis. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

      Sentiment: Strong Buy

3.04-0.05(-1.62%)Apr 28 4:00 PMEDT